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Multiple sclerosis (MS) is an inflammatory disease of the CNS that is associated with demyelination and axonal loss, resulting in severe
neurological handicap. Current MS therapies mostly target neuroinflammation but have only a little impact on CNS myelin repair.
Progress toward treatments that enhance remyelination would therefore representmajor advances inMS treatment. Here, we examined
the ability of TFA-12, a new synthetic compound belonging to tocopherol long-chain fatty alcohols, to promote oligodendrocyte regen-
eration and remyelination in experimental models of MS. We showed that TFA-12 significantly ameliorates neurological deficit and
severity ofmyelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) inmice. Histological eval-
uation of mouse EAE spinal cords showed that TFA-12 treatment reduces inflammation, astrogliosis, and myelin loss. Additionally, we
demonstrated that TFA-12 accelerates remyelination of focal demyelinated lesions induced by lysolecithin injections.We also found that
this compound induces the differentiation of oligodendrocyte precursor cells intomature oligodendrocytes through the inhibition of the
Notch/Jagged1 signaling pathway. Altogether, our data provide important proof of principle indicating that TFA-12 could be a potential
therapeutic compound for myelin repair in MS.
Introduction
Multiple sclerosis (MS) is an inflammatory disease of the CNS,
leading to chronic demyelination and axonal loss (Compston and
Coles, 2008; Trapp and Nave, 2008). MS lesions can be repaired
by endogenous oligodendrocyte precursor cells (OPCs)
(Fancy et al., 2011). However, in most cases, remyelination
fails, resulting in irreversible neurological disability (Chang et
al., 2002). Current treatments mainly target the inflammatory
component of the disease but have little impact on myelin
repair. Therefore, development of therapies promoting remy-
elination and neuroprotection would represent an important
advance in MS treatment.
Several factors modulating oligodendrocyte differentiation
may provide effective pharmacological targets to enhance remy-
elination inMS. These factors include retinoidX receptor gamma
(Huang et al., 2011), Wnt/ catenin (Fancy et al., 2009; Ye et al.,
2009), Notch1/Jagged (John et al., 2002; Nakahara et al., 2009;
Zhang et al., 2009), and the myelin inhibitor LINGO-1 (Mi et al.,
2009). Another strategy to stimulate endogenous myelin repair
relies on the delivery of growth factors that regulate survival,
proliferation, or differentiation of oligodendroglial cells (Connor
and Dragunow, 1998; Decker et al., 2005). However, despite
some promising results in experimental models, attempts to de-
velop clinical trials based on growth factors have been mainly
unsuccessful (Thoenen and Sendtner, 2002). The major limita-
tions of growth factor-based strategies are caused by their poor
penetration into the CNS, low stability, and wide-range activities
(Xie and Longo, 2000). Thus, recent efforts have been focused on
the development of syntheticmolecules, which have the ability to
mimic biological effects of neurotrophins with limited side
effects.
A number of hybrid molecules that act on regeneration and
neuroprotection are derived from-tocopherol, amember of the
vitamin E family that is widely used in clinical practice because of
its antioxidant and anti-inflammatory properties (Kapelusiak-
Pielok et al., 2005). Moreover, fat-soluble vitamins, including
Received Feb. 19, 2013; revised May 13, 2013; accepted June 3, 2013.
Author contributions: B.N.O. designed research; B.B., T.H., C.G., N.M.M., C.C., L.G., A.K., C.K., andM.F. performed
research; D.C. contributed unpublished reagents/analytic tools; B.B., T.H., C.G., N.M.M., C.C., L.G., A.K., C.K., A.B.-
V.E., E.M., P.H., and B.N.O. analyzed data; B.N.O. wrote the paper.
This work was supported by the Institut National de la Sante´ et de la Recherche Me´dicale, University of Luxem-
bourg and the Institut Hospitalo-Universitaire de Neurosciences Translationnelles de Paris, A-ICM, Investissements
d’Avenir ANR-10-IAIHU-06. B.B. was the recipient of a fellowship from the Luxembourg Ministry of Culture, Higher
Education, and Research. C.C. was supported by Inserm and Pierre and Marie Curie University, and N.M.M. was
supportedby the FrenchMultiple Sclerosis Foundation (ARSEP) and the EuropeanLeukodystrophy foundation (ELA).
We thank Violetta Zujovic, Aurelia Sahel, Corinne Bachelin, and Cyrille Deboux for helpful comments and critical
reading of this manuscript.
The authors declare no competing financial interests.
Correspondence shouldbeaddressed toDr. BrahimNait Oumesmar, CRICM, Inserm-UPMC,UMRS975, CNRSUMR
7225, Baˆtiment ICM, 47 bd de l’Hoˆpital, 75651 Paris Cedex 13, France. E-mail: brahim.nait_oumesmar@upmc.fr.
DOI:10.1523/JNEUROSCI.0774-13.2013
Copyright © 2013 the authors 0270-6474/13/3311633-10$15.00/0
The Journal of Neuroscience, July 10, 2013 • 33(28):11633–11642 • 11633
-tocopherol, are considered as important diseasemodulators in
MS and show beneficial outcomes on white matter damage in
experimental models (Kryzhanovskiı˘ et al., 1984; Torkildsen et
al., 2013). Among these compounds, the tocopherol long-chain
fatty alcohol TFA-12 is a synthetic molecule that combines an
-tocopherol moiety and a neurotrophic -alkanol side chain
with 12 carbon atoms (Muller et al., 2004). TFA-12 is a potent
inhibitor of microglial activation in vitro and decreases secretion
of nitric oxide and tumor necrosis factor- (TNF) (Muller et al.,
2004). Furthermore, TFAs are able to cross the blood–brain bar-
rier when peripherally administrated in a ratmodel of hippocam-
pal injury (Borg et al., 1990).
In the current study, we analyzed the ability of TFA-12 to
improve clinical recovery and repair of demyelinated lesions in
two complementary rodent models ofMS, the experimental au-
toimmune encephalomyelitis (EAE) and the lysolecithin
(LPC)-induced demyelination.We demonstrated that TFA-12
significantly enhances clinical recovery fromEAE, which correlated
with reduced inflammation, astrogliosis, and demyelination. Im-
portantly, we showed that TFA-12 accelerates remyelination by
promotingOPCdifferentiation through the inhibition of theNotch
signaling pathway.
Materials andMethods
EAE induction and TFA-12 treatment. All experiments were performed
according to European Union regulations and Inserm ethical commit-
tee (authorization A-75–1024; 10/26/2012) guidelines. Twelve-week-old
C57BL/6 female mice (n 40; Janvier) were immunized subcutaneously
with an emulsion consisting of 200 g of synthetic myelin oligodendro-
cyte glycoprotein (MOG)35–55 peptides (NeoMPS) in complete Freund’s
adjuvant (BD Biosciences), supplemented with 500 g of heat-
inactivated Mycobacterium tuberculosis (strain H37Ra; BD Biosciences).
Mice were given intravenous injections of pertussis toxin (List Biological
Laboratories) on the day of the immunization and 48 h later and were
divided in two experimental groups. Animals were scored daily for clin-
ical signs (0, healthy; 1, loss of tail tone; 2, hindlimb weakness; 3,
hindlimb paralysis; 4, scale 3 plus forelimbweakness; 5, death). Fromday
12 postimmunization (12 dpi) until the end of the experiment, one group
(n 20mice) received intraperitoneal injections dailywith TFA-12 (0.39
mg/kg in 1% ethanol/saline solution) and the other (n 20) received the
vehicle solution only. Animalswere killed at 25 dpi. TFA-12 synthesis was
performed as described previously (Muller et al., 2004), and the dose of
TFA-12 used in EAE experiments was based on the optimal concentra-
tion eliciting OPC differentiation in vitro (see below). Similar results
were reproduced in three independent experiments.
Tissue processing and histological staining. Animals were perfused un-
der deep anesthesia with 4% paraformaldehyde (PFA) in 0.1 M PBS.
Spinal cords were removed, postfixed in the same fixative at 4°C for 2 h,
and incubated overnight in 15% sucrose/0.1 M PBS. Tissues were frozen
in isopentane (60°C), and 12mcoronal sectionswere performedwith
a Reichert cryotome (Leica). Sections were stained with Luxol fast blue
(LFB; to visualize myelin; Sigma-Aldrich) and Oil Red O (ORO; for
macrophages containing myelin debris; Sigma). For LFB staining, sec-
tions were dehydrated and incubated in a 0.1% LFB solution at 37°C
overnight. Slides were then cooled at 4°C, incubated in a 0.05% lithium
carbonate solution, and cleared in 70% ethanol. Slides were next stained
with cresyl violet, dehydrated, andmounted in Eukitt (O. Kindler). ORO
staining was performed in 0.15%ORO/36% triethyl phosphate solution.
Figure 1. TFA-12 inhibits astroglial andmicroglial activation in vitro. A, Molecular structure
of TFA-12.B, RT-PCR analysis of gfap, vimentin,N-cadherin,NosII, and Tnf- gene expression in
astrocyte primary cultures, treated or untreatedwith TFA-12 (106 M) andwith orwithout LPS
(1g/ml). TFA-12 inhibits both astrogliosis and inflammatory gene response. C, RT-PCR gene
expression analysis in MMGT12 microglial cells. RNA extraction was performed after 6 h of
incubation with TFA-12 (105 M), with or without LPS activation (0.01g/ml). Expression of
NosII, Il-1, and Tnf- transcripts in TFA-12-treatedMMGT12 cells are significantly decreased.
-Actin was used as an internal control. D, E, ELISA quantification of TNF (D) and IL1 (E)
protein levels in LPS-stimulated MMGT12 microglial cultures treated and untreated with
TFA-12 for 24 h. TFA-12 inhibits both TNF- and IL-1 secretion. Data aremean SEM values
obtained from three experiments, each conducted in independent cultures (n 3). *p 0.01,
Student’s t test. Ctr, Control.
Figure 2. TFA-12 improves the clinical course of MOG-induced EAE. A, EAE was induced in
C57BL/6 mice by immunization with MOG35–55 peptides, and clinical scores were evaluated
daily. TFA-12 (0.39 mg/kg) or saline solution alone was injected daily from disease onset at 12
dpi. TFA-12 injections improves significantly (*p 0.05) the mean clinical scores in EAE mice
compared with vehicle treatment (n 20 for each group) from 20 to 25 dpi. B, C, LFB-cresyl
violet staining of spinal cord sections from vehicle-treated (B) and TFA-12-treated (C) EAEmice
at 24 dpi. Vehicle-treated mice show large inflammatory foci (arrows) in the spinal cord white
matter (B), whereas few very cellular infiltrates are detected in spinal cords of TFA-12-treated
mice (C). Scale bar, 100m.
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Sections were next rinsed in water, incubated with hematoxylin, and
mounted in Fluoromount medium (Clinisciences).
Lysophosphatidylcholine-induced demyelination and ultrastructural
analysis of remyelination. Ten-week-old C57BL/6 mice were used to per-
form focal demyelinated lesions in spinal cords by stereotaxic injections
of 1% lysophosphatidylcholine (LPC; Sigma-Aldrich) in 0.9% NaCl so-
lution (1 l) into the dorsal funiculus, as described previously (Nait
Oumesmar et al., 1995). After surgery, animals were split into control
and experimental groups. TFA-12 compound was administered by daily
intraperitoneal injections (0.39mg/kg) from day 5 to day 14. The control
group was given injections of vehicle solution only. At 15 d after LPC
injection, lethally anesthetizedmice were perfused with 2.5% glutaralde-
hyde/2%PFA in PBS. Spinal cords were dissected, postfixed in 2%OsO4,
and contrasted with 5%uranyl acetate before embedding in Epon. Ultra-
thin sections were cut on a vibratome and viewed using a Philips electron
microscope. The number of remyelinated axons, identified by their thin
myelin sheaths, was quantified on ultrathin sections of the lesions using
ImageJ software. Data were expressed as the percentage of total axons
within the lesion area. Quantification was performed in a blind fashion
by two independent investigators.
Cell cultures. The CG4 cell line was cultured on polyornithine–lamin-
ine and expanded in N1/B104 (70/30 v/v) medium, as described previ-
ously (Louis et al., 1992). For differentiation assays, N1/B104 was
replaced by N1 containing TFA-12 at 5  107 M or N1 alone, and the
medium was changed daily. TFA-12 concentration of 5  107 M was
selected based on dose–response studies. This concentration elicited an
optimal pro-differentiation effect onCG4 cells, whereas TFA-12 concen-
trations over 106 M had toxic effects. Primary astrocyte cultures were
prepared from newborn Wistar rat pups, as reported previously (Morga
et al., 2000). The mouse microglial cell line MMGT12 (gift from Dr. E.
Vanmechelen, Innogenetics, Gent, Belgium)
was cultured in DMEM/Ham’s F12 (1/1), sup-
plemented with 2% fetal calf serum (FCS; In-
vitrogen), 1% Insulin/Transferrin/Selenium
(ITS, Invitrogen) and 15% filtered conditioned
medium of WEHI cells (American Type Cul-
ture Collection). This cell line has characteris-
tics of primarymicroglia (Kieseier et al., 2007).
For astrocyte cultures, TFA-12 treatment was
performed at 106 M for 24 h with or without
LPS (1 g/ml). This concentration was deter-
mined in dose–response experiments and elic-
ited a significant response in astrocyte cultures.
MMGT12 cultureswere treatedwithTFA-12 at
the effective concentration of 105 M (Muller
et al., 2004) with or without LPS stimulation
(0.01 g/ml) for 6 and 24 h to perform RT-
PCR and ELISA experiments, respectively.
RT-PCR analysis. Total RNA was purified
from astrocyte and microglia cultured cells, as
described previously (Grandbarbe et al., 2007).
RNA analysis was performed with the RNA
electrophoresis Experion system (Bio-Rad) to
check their quality and the absence of genomic
contamination. One microgram of total RNA
was reverse transcribed using the ImProm-II
Reverse Transcription System (Promega) with
0.5 g/reaction oligo(dT). For PCR amplifica-
tion, specific oligonucleotide primer pairs
(available upon request) were incubated with 1
l of cDNA and 0.8 U of TaqDNA polymerase
in 25 l of PCR Master Mix (Promega). Typ-
ical cycle conditions were 30 s at 94°C, 30 s at
55°C, and 1 min at 72°C. Twenty microliters
of the resulting mix were then separated on a
2% agarose gel and visualized by ethidium
bromide staining on a transilluminator.
Measurement of TNF- and IL- produc-
tions. TNF and IL-1 concentrations were
measured using the DuoSet ELISA/Assay De-
velopment kit (R&D Systems). Intracellular IL-1 was measured by col-
lecting cells in hypotonic buffer. TNF production was measured in the
culture supernatant 24 h after LPS exposure. The protein content of the
lysates was determined using Dye Reagent (Bio-Rad) by measuring the
absorbance at the wavelength of 595 nm, using bovine serum albumin
standards. The data represent mean SEM values from at least three
independent experiments.
Differentiation assays in the presence of the Notch agonist Jagged 1.
For differentiation experiments of CG4 cells in the presence of Notch
agonist Jagged1/Fc, N1/B104 was replaced by N1 supplemented with
TFA-12 at 5  107 M or by N1 alone, with or without the soluble
form of the Notch agonist Jagged1 (recombinant rat Jagged1/Fc chi-
mera; R&D Systems). The medium was changed daily, and differen-
tiation was performed for 3 d. A dose–response curve of the effects of
Jagged1 on CG4 cells was first established in N1mediumwith increas-
ing concentrations of Jagged1/Fc (ranging from 0 to 8 g/ml). The
Jagged1/Fc concentration of 4 g/ml was found to inhibit the gener-
ation of O4 oligodendrocytes by fivefold compared with control
cells, after 3 d in differentiation condition. This concentration was
therefore used in these experiments.
Oligodendroglial primary cultures. Primary cultures of oligodendro-
cytes were performed basically as described by McCarthy and de Vellis
(1980). Briefly, cerebral hemispheres were dissected from newborn
transgenic EGFP rats (Okabe et al., 1997), freed of meninges, and disso-
ciated by gentle repetitive pipetting in a mixture of DMEM/F-12 (1:1)
containing 1% streptomycin/penicillin supplemented with 10% fetal calf
serum. The cell suspension was seeded in poly-L-lysine-coated flasks.
After 14 d in culture, microglia was separated by shaking for 45min in an
orbital shaker at 250 rpm/min, and oligodendrocytes were separated
Figure 3. Inflammation, astrogliosis, and demyelination are reduced by TFA-12 treatment. Thoracic spinal cord sections from
vehicle-treated (B, E, H, K ) and TFA-12-treated (A, D, G, J ) mice were analyzed at 24 dpi. A, B, CD45 immunohistochemistry on
spinal cord sections of vehicle-treated (A) and TFA-12-treated (B) EAE mice reveals immune foci (dashed lines) in the dorsal
funiculus. C, The number of CD45 cells is decreased by 2.8-fold in TFA-12-treated mice compared with controls. D, E, In
vehicle-treated mice, demyelinated lesions are characterized by the lack of MBP staining and myelin debris (D), whereas demy-
elination is barely visible in TFA-12-treatedgroups (E).F, Theextent of demyelination is 4.2-fold lower in TFA-12-treatedmice than
in controls. G–I, GFAP astrogliosis is also drastically reduced by TFA-12 treatment. J–L, ORO staining (red) reveals intense
macrophage activity in EAE lesions from vehicle-treated mice (J ), whereas macrophage activity is significantly reduced under
TFA-12 conditions (K, L). All quantifications weremade on three independent experiments. *p 0.05, Student’s t test. Scale bar,
50m.
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from the astrocytes by continuous shaking overnight at 300 rpm/min.
The cell suspension was filtered and centrifuged at 1000 rpm for 5 min.
The pellet containing the oligodendrocytes was resuspended in N me-
dium containing a 1:1 mixture of DMEM/F-12, 0.6% glucose, 25 g/ml
insulin, 1% N2 mix, 0.5% B27, and 0.5% HEPES and was plated in
poly-L-lysine 24-well plates (5  104 cells/well). The cell cultures were
kept for 2 d in N medium in the absence or presence of 5  107 M
TFA-12. Themediumwas changed every day. Cells were fixed in 4%PFA
and used for morphological and immunocytochemical analyses.
Immunochemistry. Sections were incubated overnight with primary
antisera at 4°C, rinsed, and incubated with the appropriate secondary
antibodies for 1 h at 20°C. They were next counterstained with bis-
benzimide (Hoescht 33342; Sigma-Aldrich), washed, and mounted
with Fluoromount (Clinisciences). For in vivo experiments, the fol-
lowing antibodies were used: rabbit anti-MBP (1:100; Millipore) and
mouse anti-MOG (1:20, 8-18C5 hybridoma; gift from C. Linington,
University of Aberdeen, Aberdeen, UK) for myelin staining; rat anti-
CD45 (1:100; Invitrogen) for immune cells; rabbit anti-NG2 (1:100;
Abcys) for OPCs; and mouse anti-APC7 (1:100, clone CC1; Calbio-
chem) for postmitotic oligodendrocytes. For in vitro experiments,
cells were incubated with O4 (1:1; American Type Culture Collection)
or GalC (1:1; Millipore) primary antibodies for 30 min at 20°C. For
Ki67 staining (1:100; BD Biosciences), cells were fixed with ice-cold
2% PFA, rinsed twice with PBS, and incubated with the primary
antibody. Cells were incubated with secondary antibodies for 30 min,
rinsed in PBS, counterstained with Hoescht 33342, and mounted with
fluoromount (Clinisciences). Slides and cells were analyzed under a
DMRA fluorescence microscope (Leica).
Quantification. In vitro, cell counts were established on three separates
experiments. Quantifications are mean  SEM values of the data col-
lected from at least six coverslips for each experiment. To avoid subjec-
tive selection,microscopic fields were randomly selected, and at least 500
cells were counted for each coverslip. For EAE experiments, cell counts
were performed in CD45 EAE lesions with at least six animals per
group. For each animal, staining and cell counts were made on 15 sec-
tions from at least three distinct slides covering all spinal cord levels. To
limit experimental bias, immunolabelings were performed at the same
time and images were taken with the same acquisition parameters. For
each marker, counts were performed in EAE lesions defined by MBP and
CD45 coimmunolabeling on adjacent sections. Measurements were per-
formed in CD45 foci and processed with ImageJ 1.34S. For NG2 staining,
positive cells with DAPI nuclei were quantified and separated from each
other using high-resolution fluorescencemicroscopy as reported previously
(Reynolds et al., 2002; Dawson et al., 2003).
Real-time PCR. Total RNAs were isolated using Trizol reagent (Invit-
rogen). DNA contamination was removed with DNaseI treatment, and 1
g of RNA was synthesized into first-strand cDNA using the Thermo-
script RT-PCRSystemkit (Invitrogen). Three replicates of real-timePCR
experiments were performed using an ABIprism 7000 sequence detec-
tion system with Taqman gene expression assay probes (Applied Biosys-
tems). After real-time PCR experiments, theCt numberwas extracted for
both the reference gene (GAPDH ) and the target gene with automatic
baseline and manual threshold. We used the Ct model to determine
fold increases and the Wilcoxon test on Ct for statistical analysis. Data
are mean SEM of at least three separate experiments.
Statistical analysis.The Student’s t test andMann–WhitneyU test were
used to assess statistical significance (SigmaStat 3.1; Systat Software). The
p values0.05 were considered significant.
Results
TFA-12 inhibits astroglial andmicroglial activation in vitro
As a first attempt to define the biological activity of TFA-12 (Fig.
1A), we tested whether this molecule modulates astroglial and
microglial activation induced by LPS treatment in vitro (1 and
0.01g/ml for astroglial andmicroglial cultures, respectively). In
primary astrocyte cultures, RT-PCR experiments for Gfap, Vi-
mentin, and N-Cadherin revealed that TFA-12 reduced the ex-
pression of astroglial genes, even in response to LPS activation
(Fig. 1B). NosII and Tnf gene expression were also significantly
downregulated in astrocyte cultures treated with TFA-12. We
also noticed that LPS treatment alone slightly reduced the expres-
sion of astroglial transcripts, as reported previously (Selmaj et al.,
1991; Murphy et al., 1995). Similar experiments were also per-
formed on the primary microglial cell line (MMGT12 cells) in-
duced to produce Tnf-, Il-1, and NosII in response to LPS
stimulation for 24 h. The addition of TFA-12 to LPS-treated cul-
tures effectively inhibited the expression of major mediators of
microglial activation such as Tnf- and NosII (Fig. 1C). This
inhibition was also confirmed by ELISA analysis of TNF- (Fig.
1D) and IL-1 (Fig. 1E) protein levels in TFA-12-treated
MMGT12 culture supernatants. These data demonstrate that
TFA-12 is an effective inhibitor of astroglial and microglial acti-
vation and, therefore, may prevent inflammatory insults in the
CNS.
TFA-12 enhances clinical recovery of MOG-induced
EAE disease
Having established that TFA-12 had anti-inflammatory proper-
ties in vitro, we next tested whether this compound had a benefi-
cial effect on the clinical course of MOG-induced EAE in mice.
Figure 4. TFA-12 treatment reduced microglial activation in MOG-induced EAE. Coronal
spinal cord sections from vehicle-treated (A,B) and TFA-12-treated (D–F ) EAEmice stained for
MOG (A, D) and F4/80 (B, E) at 24 dpi. EAE lesions are delimited by dashed lines. A, B, D, E, In
vehicle-treated spinal cords, lesions lacking MOG labeling (A) were filled with numerous acti-
vated F4/80microglia (B), whereas in TFA-12-treatedmice (D), F4/80microglial cells are
strongly reduced (E). C, F, Merge fields are shown. Scale bar, 50m.
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This EAEmodelmimics important pathological hallmarks ofMS
lesions, with inflammatory lesions occurringmainly in the spinal
cord and resulting in chronic demyelination (Hobom et al.,
2004). Moreover, in this well characterized MOG–EAE model,
the onset of clinical symptoms (score of 0.5–1) is strongly corre-
lated with the occurrence of inflammatory white matter lesions,
which extendwith disease progression (Jones et al., 2008; Recks et
al., 2011). Thus, this model is suitable for evaluating the thera-
peutic potential of TFA-12 in MS. EAE-induced mice were given
daily injections of TFA-12 (0.39 mg/kg, n  20) or the vehicle
alone (saline solution with 0.2% alcohol, n 20) from the onset
of clinical signs at 12 dpi until 25 dpi. Mice treated with the
vehicle alone showed typical EAE disease course, with clinical
scores increasing progressively from12 to 21 dpi and reaching 2.5
(Fig. 2A). In contrast, TFA-12-treated mice displayed a signifi-
cant reduction of the mean clinical score, which was never1.5.
To validate the clinical improvement induced by TFA-12, we
stained spinal cord sections from EAE mice with cresyl violet for
cellular infiltrates. This staining revealed numerous inflamma-
tory foci in thewhitematter of vehicle-treatedmouse spinal cords
(Fig. 2B), whereas TFA-12-treated mice showed much lower cel-
lular infiltrations (Fig. 2C).
TFA-12 reduces inflammation, astrogliosis, and
demyelination in EAE
To further confirm the anti-inflammatory properties of TFA-12,
we stained spinal cord sections from EAE mice at 25 dpi with
CD45 and MBP to identify leukocytes and demyelinated lesions.
In TFA-12-treated mice, CD45 staining revealed very few leuko-
cyte infiltrates often disseminated in the spinal cord white matter
tracts (Fig. 3B), whereas in EAE mice treated with the vehicle
alone, numerous CD45 cells were detected in lesioned areas
(Fig. 3A). We quantified the number of CD45 cells in dorsal
funiculus at the thoracic level in both groups and demonstrated
that the number of leukocytes was decreased by 2.8-fold in TFA-
12-injected EAEmice comparedwith controls (Fig. 3C). Further-
more, microglial activation assessed by F4/80 immunolabeling
was also strongly attenuated in the TFA-12-treated group (Fig.
4A–C) compared with vehicle-treated EAE mice (Fig. 4D–F).
These results indicate that TFA-12 acts a potent inhibitor of CNS
inflammation. We next analyzed the extent of demyelination in
CD45 EAE lesions in both experimental groups using MBP
immunohistochemistry (Fig. 3D,E). Vehicle-treated mice showed
large demyelinated lesions filled with MBPmyelin debris (Fig.
3D), whereas TFA-12-treated mice exhibited much smaller de-
myelinated areas in similar thoracic levels (Fig. 3E). Quantifica-
tion of MBP-negative areas revealed a significant reduction of
demyelination in the TFA-12 treatment group (Fig. 3F).We next
examined the effects of TFA-12 on astrogliosis in EAE spinal cord
sections using immunolabeling for GFAP. Quantification of
Figure 5. TFA-12 impacts on oligodendroglial cells in EAE lesions. A, B, Immunolabeling for
NG2 OPCs in EAE lesions of vehicle-treated (A) and TFA12-treated (B) mouse spinal cords. C,
Cell counts in EAE lesions reveal a significant reduction in the number of NG2 cells (arrows),
under TFA-12 conditions. D, E, CC1 immunolabeling (arrows) in spinal cord EAE lesions from
vehicle- and TFA-12-treated mice. F, Quantification of CC1 cells shows a 1.6-fold increase of
the number CC1 oligodendrocytes in TFA-12-treated groups. The dashed lines outline the
border of EAE, as defined by CD45 immunolabeling on adjacent sections. **p 0.01, Student’s
t test. Scale bar, 50m.
Figure 6. TFA-12 treatment enhances amount of remyelinated axons in LPC-induced le-
sions. A, Schematic representation of LPC-induced demyelination in the mouse spinal cord
dorsal funiculus.B, Toluidine blue semithin section illustrating LPC-induced demyelination at 2
dpi. C, D, Ultrathin micrographs of the lesions in vehicle-treated (C) and TFA-12-treated (D)
mice at 15 dpi. TFA-12 treatment enhances the number of remyelinated axons, identified by
their thin myelin sheaths (D, asterisks), whereas vehicle-treated mice had significantly fewer
remyelinated axons (C). E, Quantification of remyelinated axons over the total number of axons
within the lesion shows a significant increase under TFA-12 treatment. ***p 0.001, Stu-
dent’s t test. Scale bars: B, 100m; C, D, 5m.
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GFAP immunoreactivity revealed a 2.4-
fold reduction of reactive astrogliosis after
TFA-12 administration (Fig. 3G–I). To
assess the effects of TFA-12 treatment on
active demyelination, we also used ORO
staining that specifically labels myelin de-
bris in macrophages. In vehicle-treated
spinal cords, lesions showed intense ORO
staining, indicating that active demyelina-
tion was still occurring (Fig. 3J). In con-
trast, spinal cord lesions from TFA-12-
treatedmicewere rarely labeledwithORO
(Fig. 3K). Quantification of ORO labeling
revealed a significant decrease under
TFA-12 conditions (Fig. 3L), confirming
that active demyelination was prevented
by this compound.
We also analyzed the effects of TFA-12
on oligodendroglial lineage cells, using
NG2 and CC1 immunohistochemistry.
Our results indicated that TFA-12 treat-
ment reduced significantly the density of
NG2 OPCs (Fig. 5A–C) at the expense
of CC1 differentiated oligodendrocytes
in EAE lesions (Fig. 5D–F). In contrast,
the density of NG2 OPCs was 1.5-fold
higher in vehicle groups, and the number
of CC1 cells decreased in similar range
(Fig. 5C,F), suggesting that this com-
pound induces oligodendrocyte differen-
tiation. Overall, these results indicate that
TFA-12 lead to histological improvement
of inflammation, astrogliosis, and demy-
elination and further suggest that this
compound may enhance the differentia-
tion of endogenous OPCs into remyeli-
nating oligodendrocytes.
TFA-12 promotes remyelination of
focal demyelinated lesions
To test whether TFA-12 could promote
remyelination, we used the LPC-in-
duced demyelination model of the mouse
spinal cord (Fig. 6A,B). Compared withMOG-induced EAE, de-
myelination and remyelination are temporally distinct with
demyelination occurring at 1 dpi after LPC treatment, fol-
lowed by a proliferation/recruitment phase of the endogenous
OPCs, a differentiation phase beginning at 7 dpi, and a remy-
elination process starting around 14 dpi and almost complete
at 30 dpi. Therefore, this model provides a significant time
frame for quantitative analysis of the remyelination process
after TFA-12 treatment. Two groups of mice were analyzed: a
control group that received injections of the vehicle solution alone
(n 6) and an experimental group of mice that received intraperi-
toneal injections of TFA-12 (n 6). TFA-12 treatmentwas initiated
at 5 dpi, when local inflammation is fading away andOPC differen-
tiation onsets, and further continued daily for 10 d. Ultrastructural
analysis of remyelinated versus demyelinated axons was performed
onultrathin sections through the lesionsat 15dpi.We found that the
percentage of remyelinated axons identified by thinmyelin sheaths,
over the total number of axons, was significantly increased in LPC
lesions frommice treated with TFA-12 (Fig. 6D,E) compared with
controls (Fig. 6C,E) (76.8 3.6% in TFA12 vs 33.5 4.8% in con-
trols). As expected in the LPC model of demyelination, we found
that axonal density remained unchanged in both experimental
groups (vehicle, 49.9  8.4  103 vs TFA12: 50.5  3.1  103
axons/mm2). These data clearly demonstrate that TFA-12, in addi-
tion to its anti-inflammatory properties, promotes remyelinationby
endogenous OPCs.
TFA-12 promotes oligodendrocyte differentiation in vitro
To further examine whether the remyelinating activity of TFA-12
is related to a direct effect onOPCs, we analyzed the properties of
this compound in CG4 (Louis et al., 1992) and primary OPC
cultures. CG4 cells were maintained as immature A2B5/
O4- OPCs in N1 medium supplemented with B104 conditioned
medium and induced to differentiate in N1 medium without
serum for 5 d.We assessed the effects of TFA-12 (5 107 M) on
CG4 cells in differentiation medium, using immunocytochemis-
try for A2B5 forOPCs,O4which labels pre-oligodendrocytes and
GalC for differentiated oligodendrocytes. Under differentiation
conditions, TFA-12 treatment for 48 h increased by 2.5-fold the
Figure 7. TFA-12 promotes CG4 cell differentiation. CG4 oligodendroglial cells were differentiated in N1medium (A,D,G, J ) or
in N1 supplemented with 5 107 M TFA-12 (B, E, H, K ) for 48 h for O4 and Ki67 and 5 d for GalC staining. A, B, The number of
O4 oligodendrocytes (arrows) is increased by TFA-12 treatment (B) comparedwith untreated cultures (A). C, The percentage of
O4 oligodendrocytes is 2.5-fold higher in TFA-12-treated than untreated cultures. D, E, Morphology of untreated (D) and
TFA-12-treated (E) O4 oligodendrocytes. F, Quantification of O4 oligodendrocytes, according to their number of processes,
shows that TFA-12 promotes OPC differentiation. G,H, Proliferating Ki67 cells (arrows) are reduced in N1medium plus TFA-12
(H ) comparedwithN1alone (G). I, Quantification of thepercentageof Ki67 cells shows an11-fold reduction of cell proliferation.
J, K, GalC immunostaining of CG4 culture after 5 d of differentiation in N1 medium alone (J ) or N1 supplemented with 5
107 M TFA-12 (K ). L, The number of GalC differentiated oligodendrocytes was significantly enhanced by TFA-12 treatment.
*p 0.05; **p 0.01, Student’s test. Scale bars: A, B, G, H, J, K, 50m; D, E, 25m.
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number of O4 oligodendrocytes compared with control cul-
tures (Fig. 7A–C). The degree of differentiation of CG4 cells was
also evaluated by counting the total number of O4 oligoden-
drocytes with zero to two, three to four, and more than four
processes emerging from the cell body. Under TFA-12 treatment,
CG4 cells were significantlymore branched compared with vehicle-
treated cells (Fig. 7D–F). Furthermore, the differentiation activity of
TFA-12 was confirmed by the significant increased number of
GalC differentiated oligodendrocytes (19 0.17%ofGalC cells
in TFA-12medium vs 14 0.14% inN1medium alone; Fig. 7J–L).
As differentiation is often correlated with cell-cycle exit, we noticed
that the number of Ki67 cells was drastically reduced by 11-fold
under TFA-12 conditions (Fig. 7G–I).
Similar experiments were next performed with primary OPC
cultures purified from newborn transgenic rat pups expressing
GFP under the control the ubiquitous -actin promoter (Okabe
et al., 1997). This reporter line allowed us to follow morpholog-
ical changes associated with cell differentiation based on GFP
fluorescence. To test the effect of this compound on primary
OPC differentiation, we examined cell proliferation using Ki67
labeling after 2 d in Nmedium plus TFA-12 (5 107 M) or in N
medium plus vehicle. Interestingly, the number of Ki67 cells
was significantly reduced under TFA-12 conditions compared
with controls (Fig. 8A–C). Furthermore, the number of GalC/
GFP differentiated oligodendrocytes significantly increased
under TFA-12 conditions, and GalC-expressing cells exhibited a
ramified morphology with complex pro-
cesses (Fig. 8D–F). Importantly, the pro-
differentiation activity of TFA-12 was
confirmed by the significant increase of
MBPoligodendrocyteswithmyelin-like
sheaths under TFA-12 conditions (Fig.
8G–I). Altogether, our results indicate
that TFA-12 acts as a potent promyelinat-
ing compound by inducing OPC
differentiation.
TFA-12 acts as an antagonist of the
Notch signaling pathway
To get a better insight into the mecha-
nisms bywhich TFA-12 triggers oligoden-
drocyte differentiation, we next tested
whether this compound could modulate
the Notch signaling pathway. Notch plays
a crucial role in oligodendrocyte develop-
ment, and activation of Notch receptors
was shown tomaintainOPCs at an imma-
ture stage and to inhibit their differentia-
tion (Park et al., 2005; Yoon and Gaiano,
2005). Moreover, Notch activation in-
duces the expression of the downstream
effectors Hes1 and Hes5, which down-
regulate expression of bHLH transcrip-
tion factors such as Mash1. Interestingly,
both Hes1 and Hes5 gene expression, as-
sessed by real-time PCR, were decreased
by fourfold in CG4 cultures treated with
TFA-12 concentrations of 108 and 106
M (Fig. 9A). Inhibition of Hes genes in
TFA-12-treated cultures (106 M) was
further correlated with a fourfold increase
of Mash1 transcripts, a bHLH factor in-
volved in oligodendrocyte specification
and differentiation (Parras et al., 2007; Sugimori et al., 2007).
To further validate TFA-12 as an antagonist of the Notch
pathway, CG4 differentiation was performed for 3 d in N1 me-
dium alone, N1 supplemented with Jagged1/Fc (4 g/ml), or N1
medium containing Jagged1/Fc (4g/ml) andTFA-12 (5 107
M). Cell counts showed a significant decrease of O4 oligoden-
drocytes in N1Jagged/Fc medium compared with N1 alone,
indicating that Jagged activation of the Notch signaling pathway
in OPCs prevented their differentiation, as described previously
(Wang et al., 1998; Genoud et al., 2002). Interestingly, Jagged1-
mediated inhibition of OPC differentiation was significantly re-
versed by TFA-12 (20 0.033% of O4 cells in N1Jagged1/Fc
vs 30 0.031% in N1Jagged1/FcTFA-12) (Fig. 9B), demon-
strating that this compound acts as potent inhibitor of the Jagged/
Notch signaling pathway. Altogether, our results provide
compelling evidence indicating that TFA-12 induces oligoden-
drocyte differentiation through the inhibition of the Notch
pathway.
Discussion
In the present study, we showed that the tocopherol derivative
TFA-12 reduces the severity and improves clinical recovery of
EAE in mice. These effects were correlated with the reduction of
several deleterious parameters of the EAE pathological process,
including inflammation, astrogliosis, and demyelination. We also
found that TFA-12 accelerates remyelination of focal demyelinated
Figure 8. TFA-12 enhances oligodendrocyte differentiation in primary OPC cultures. Primary OPCs, prepared from CAG-GFP
transgenic newborn rat brains, were cultured 5 d in Nmedium alone or in N 5 107 M TFA-12.A,B, Ki67 immunocytochem-
istry in vehicle-treated (A) and TFA-12 treated (B) cultures.C, The number of Ki67 cells is significantly reduced in TFA-12-treated
cultures.D–F, GalC andGFP coimmunostaining in vehicle-treated (D) andTFA-12-treated (E) OPC cultures. Cells counts confirm the
significant increase in the number of GalC differentiated oligodendrocytes with complex processes (D–F ). G, H, MBP and GFP
coimmunolabeling in control (G) andTFA-12-treated (H ) cultures reveals a significant increaseofMBPmatureoligodendrocytes
bearing myelin-like sheaths (G, H, arrowheads; I ). **p 0.01; ***p 0.001, Student’s t test. Scale bar, 100m.
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lesions induced by LPC injection. Moreover, we demonstrated that
TFA-12 enhances OPC differentiation into myelinating oligoden-
drocytes through the inhibition of the Notch signaling pathway.
The anti-inflammatory properties of TFA-12 in astroglial and
microglial cultures lead us to test the therapeutic relevance of this
compound inmouse EAE, a commonmodel ofMS.We tested the
outcome of intraperitoneal injections of TFA-12 in MOG-
induced EAE and found that thismolecule at a dose of 0.39mg/kg
attenuated significantly the severity of the disease compared with
vehicle-injected groups. Histological analyses of EAE lesions re-
vealed that TFA-12 leads to a significant reduction of neuroin-
flammation. These anti-inflammatory properties may explain
the beneficial properties of this hybrid molecule on several detri-
mental components of EAE, including demyelination and astro-
gliosis. In our study, TFA-12 treatment was initiated at onset
clinical symptoms and thus when white matter lesions had al-
ready started. Since inflammation is beneficial for remyelination
(Kotter et al., 2001; Setzu et al., 2006; Hohlfeld et al., 2007),
TFA-12 treatment before disease onset may prevent inflamma-
tion and, subsequently, OPC recruitment and remyelination.
However, for the prospective design of effective therapies, vari-
ous administration routes would need to be tested in mouse
models of demyelination to optimize doses, duration, and long-
term effects of TFA-12.
We also demonstrate that astrogliosis was attenuated in EAE
lesions of TFA-12-treated mice. This finding was also supported
by our in vitro data indicating that LPS-activated astrogliosis was
inhibited by TFA-12, as evidenced by reduced levels of NosII,
gfap, vimentin, and N-cadherin gene expression. Although reac-
tive astrogliosis creates a permissive environment for remyelina-
tion (Williams et al., 2007;Nash et al., 2011), it also contributes to
the formation of the glial scar expressing several inhibitory mol-
ecules preventingOPCmigration and differentiation (Back et al.,
2005; Franklin and Ffrench-Constant, 2008;), as well as axonal
regeneration (Ridet et al., 1997). By preventing the formation of
the glial scar, TFA-12 may thus contribute to the overall reduc-
tion of demyelination in MOG-induced EAE.
Our data clearly demonstrated that TFA-12 accelerates remy-
elination of focal demyelinated lesions induced by LPC injec-
tions, a model where lesions are not primarily mediated by
immune attacks. This suggests that this molecule acts directly on
oligodendroglial cells. To unambiguously assess the activity of
this compound on oligodendroglial cells, we examined its poten-
tial effects in vitro and found that TFA-12 promoted the
differentiation of OPC intomature oligodendrocytes. Although
we cannot rule out indirect mechanisms through other cells
types, we provide compelling evidence indicating that TFA-12
mediated oligodendrocyte differentiation, likely by inhibition
of Notch signaling. First, TFA-12 repressed the expression of
Notch downstream effectors Hes1 and Hes5 and concomitantly
upregulated Mash1, a bHLH transcription factor involved in
oligodendrocyte differentiation (Parras et al., 2007). Second,
TFA-12 was able to reverse the inhibition of OPC differentiation
triggered by the Notch agonist Jagged1. The precise mechanism
of this antagonistic effect may be linked to direct binding of
TFA-12 to Notch receptors or downstream in the signaling path-
way by inhibition of -secretase activity or as a result of the inhi-
bition of the nuclear translocation of Notch intracellular domain
NICD (Yoon and Gaiano, 2005). Similarly to TFA-12, it has been
reported that administration of -secretase inhibitors to EAE
mice improves clinical recovery correlating with reduced astro-
gliosis and enhanced remyelination (Jurynczyk et al., 2005). Dur-
ing developmental myelination, the Notch signaling pathway
plays a critical role in oligodendrocyte proliferation and acts as a
negative regulator of OPC differentiation (Wang et al., 1998;
John et al., 2002; Hu et al., 2003; Zhang et al., 2009). The first
downstream effectors of this signaling pathway, Hes1 and Hes5,
are part of the bHLH family of transcription factors, homologous
to the Drosophila hairy and enhancer split that represses expres-
sion of pro-neural genes, such as Mash1 and neurogenins (Yoon
and Gaiano, 2005). In OPCs, Hes1 and Hes5 are progressively
downregulated during differentiation (Wang et al., 1998). More-
over, the expression ofmajormyelin protein genes is increased in
Hes5 null mice, and Hes5 has been shown to inhibit the level of
transcription activators of myelin genes, such as Sox10 (Liu et al.,
2006). Although the role of Notch signaling on OPC differentia-
tion during remyelination remains controversial (Stidworthy et
al., 2004), a recent study using amouse line with specific deletion
of Notch1 in oligodendroglial cells showed accelerated OPC dif-
ferentiation and remyelination in the absence of Notch1 (Zhang
et al., 2009). Additionally, Notch signaling has been implicated as
a major contributor of remyelination failure in MS. Indeed, the
reexpression of Jagged1 by reactive astrocytes in chronic MS le-
sions (John et al., 2002) may activate Notch signaling in OPCs,
thereby preventing their differentiation. The activation of Notch
receptors in MS is also supported by upregulation of Hes5 in
chronic lesions (John et al., 2002). Furthermore, it has been dem-
onstrated that the binding of axonal contactin to Notch1 on
OPCs in chronicMS lesions leads to the activation of the receptor
and, consequently, to cleaved NICD. However, nuclear transloca-
tionofNICD,which is necessary forproperOPCdifferentiationand
remyelination, does not occur, resulting in remyelination block in
Figure 9. TFA-12 acts as an antagonist of the Notch signaling pathway.A, Real-time RT-PCR
ofHes1,Hes5, andMash1 gene expression levels in CG4 cells untreated and treatedwith TFA-12
for 48 h. The expression of Notch downstream effectors Hes1 and Hes5 is reduced by fourfold
under TFA-12 treatment, whereas Mash1 expression is increased by fourfold, indicating that
this compound acts as potent inhibitor of Notch signaling. TheWilcoxon test performed onCt
was used to confirm significance between TFA-12 and control groups (*p 0.05). B, Quanti-
fication of O4 cells after 3 d of differentiation in N1, N1Jagged1/Fc, and N1Jagged1/
FcTFA-12. As expected, Jagged-mediated Notch activation prevents CG4 cell differentiation
into O4 oligodendrocytes. This effect was significantly reversed by TFA-12 at 5 107 M.
*p 0.05 for N1Jagged1/Fc versus N1Jagged1/Fc TFA-12, Student’s t test. Data are
mean SEM of three independent experiments.
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chronicMS lesions (Nakahara et al., 2009). By inducingOPCdiffer-
entiation through the inhibition of Notch signaling, TFA-12 there-
fore has a remarkable remyelinating activity in experimentalmodels
of MS.
In summary, our study has revealed important insights into
the activity of TFA-12 on neuroinflammation and remyelination
in experimental models of MS, and opens new avenues for inno-
vative therapies promotingmyelin regeneration in demyelinating
diseases.
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